Amgen and the Amgen Foundation commit up to $12.5 million to support COVID-19 relief efforts
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) and the Amgen Foundation announced an initial commitment of up to $12.5 million to support U.S. and global relief efforts to address critical needs in communities impacted by the COVID-19 pandemic. The funds will be used to support emergency response efforts in Amgen's U.S. and international communities, patient-focused organizations that are mounting their own response efforts, and international relief efforts by Direct Relief and International Medical Corps.
Roche response to COVID-19 pandemic
- Details
- Category: Roche
Roche Group (SIX: RO, ROG; OTCQX: RHHBY), provided an update on the various actions the company is taking to address the COVID-19 pandemic.
On March 19, 2020, Roche confirmed initiation of a randomised, double-blind, placebo-controlled Phase III clinical trial in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), a part of the US Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR).
AstraZeneca to donate 9 million face masks to support healthcare workers around the world in the fight against COVID-19
- Details
- Category: AstraZeneca
AstraZeneca is donating nine million face masks to support healthcare workers around the world as they respond to the COVID-19 (novel coronavirus) global pandemic. AstraZeneca has partnered with the World Economic Forum's COVID Action Platform, created with the support of the World Health Organisation, to identify countries in greatest need.
Novartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response
- Details
- Category: Novartis
Novartis announced its commitment to donate up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic response. Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19.
Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) is working with the Food & Drug Administration (FDA) to initiate a randomised, double-blind, placebo-controlled Phase III clinical trial in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), a part of the US Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR), to evaluate the safety and efficacy of Actemra®/RoActemra® (tocilizumab) plus standard of care in hospitalised adult patients with severe COVID-19 pneumonia compared to placebo plus standard of care.
Free EDC software for non-profit COVID-19 related studies
- Details
- Category: Business
Italy-based EDC provider, Nubilaria srl, offers its ACTide EDC pro-bono for European non-profit COVID-19 Coronavirus related studies. The platform is made available for the agile collection of clinical data, remote patient monitoring and customizable collaborative process for the management of intensive therapies and relocation of patients according to hospital availability.
Novartis announces broad range of initiatives to respond to COVID-19 Pandemic; Creates USD 20 million global fund to support impacted communities
- Details
- Category: Novartis
Novartis today announced a broad set of measures to support the global response to the COVID-19 pandemic. These measures include the creation of a global fund to support communities around the world impacted by the COVID-19 pandemic as well as the company's decision to join two key cross-industry R&D initiatives.
More Pharma News ...
- Roche's cobas SARS-CoV-2 Test to detect novel coronavirus receives FDA Emergency Use Authorization
- U.S. Food and Drug Administration approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) for patients with hepatocellular carcinoma (HCC) previously treated with sorafenib
- Voluntis and Bristol-Myers Squibb to co-develop digital therapeutics for oncology
- International research partnership and EDCTP to invest €44m in next-generation antimalarials to combat drug-resistant malaria in Africa
- First-of-its-kind global collaboration launched to develop transformative treatment regimens for tuberculosis
- AstraZeneca completes divestment agreement with Atnahs Pharma for established hypertension medicines
- FDA accepts Roche’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer